Connect with us

Markets

Visualizing the Future of the Pharma Market

Published

on

Drug Market Outlook

Visualizing the Future of the Pharma Market

Around the world, people are living longer.

By 2050, there will be two billion people that are 60 years or older globally. Meanwhile, the amount of seniors (65+ years old) in the U.S. will double to 100 million by 2060.

To meet the needs of this aging population, we will continue to need larger quantities and more varieties of prescription drug treatments – an industry that is expected to skyrocket to $1.2 trillion in size by 2024.

Drug Sales, by Segment

Today’s infographic comes to us from Raconteur, and it highlights the most anticipated drug treatments and therapy areas for the pharmaceutical industry.

It starts by breaking down the massive pharma market into therapy segments, showing a forecast for the size and growth for each category.

Here is the data for the top 15 segments, sorted by projected worldwide prescription drug sales in 2024:

RankTherapy Area2017 sales2024 salesCAGR
#1Oncology$104B$233B+12.2%
#2Anti-diabetics$46.1B$59.5B+3.3%
#3Anti-rheumatics$55.7B$56.7B+0.2%
#4Vaccines$27.7B$44.6B+7.1%
#5Anti-virals$42.4B$39.9B-0.9%
#6Immunosuppressants$13.7B$38.1B+15.7%
#7Bronchodilators$27.2B$32.3B+2.5%
#8Dermatologicals$12.9B$30.3B+13%
#9Sensory Organs$21.6B$26.9B+3.2%
#10Anti-hypertensives$23B$24.4B+0.8%
#11Anti-coagulants$16.8B$22.9B+4.6%
#12MS Therapies$22.7B$21.5B-0.8%
#13Anti-fibrinolytics$12.7B$20.4B+7.1%
#14Anti-hyperlipidaemics$11.3B$16.4B+5.5%
#15Anti-anaemics$7.6B$15.7B+11%
Other$379B$567B+5.9%
Total$825B$1249B+6.1%

This data, which comes from a recent report from EvaluatePharma, helps showcase a few key insights.

Firstly, the oncology therapy area – which makes drugs that are used to treat various forms of cancer – is by far the largest in the pharma world with $107 billion in sales in 2017. It’s also projected to maintain its dominance going forward, growing at an impressive 12.2% CAGR to $233 billion by 2024.

Next, while sales in cancer-related drugs will be the most in absolute terms, the fastest growing treatment area is actually in immunosuppressants – a segment of drugs that make a body less likely to reject a transplanted organ, such as a liver, heart, or kidney. It’s projected that this segment will grow at 15.7% per year, eventually becoming the sixth largest pharma segment at $38.1 billion in 2024.

Lastly, while sales in the pharma market will be averaging 6.1% in annual growth as a whole, there are two major segments that will see negative annual growth going forward: Anti-virals (-0.9%) and MS Therapies (-0.8%).

The Battle Against Cancer

Currently, there are more drugs used for treating cancer than for any other type of disease or condition.

RankDisease or ConditionNumber of active drugs
#1Breast cancer727
#2Lung cancer544
#3Colorectal cancer503
#4Ovarian cancer434
#5Pancreatic cancer430
#6Type-2 diabetes407
#7Prostate cancer381
-Alzheimer's disease381

Unfortunately, even though many cancer drugs are available on the market already, the debilitating disease is still a leading cause of death. Existing drugs are used in treatments of chemotherapy or hormone therapy, but it’s clear that there is still plenty of room for progress to be made against the disease.

For these reasons – combined with the estimate that nearly 40% of Americans will be diagnosed with some form of cancer during their lifetimes – it’s no surprise to see that companies have yet even more cancer drugs in the pipeline:

RankTherapy areaNumber of drugs in pipeline
#1Anti-cancer5,212
#2Biotechnology4,751
#3Neurological2,604
#4Anti-infective2,238
#5Alimentary/metabolic2,237
#6Reformulations2,073
#7Musculoskeletal1,597
#8Dermatological929

As more drugs get approved from the above pipeline, it is projected that $1 of every $5 spent on prescription drugs in 2024 will be going towards cancer-related treatments.

Click for Comments

Markets

Will Tesla Lose Its Spot in the Magnificent Seven?

We visualize the recent performance of the Magnificent Seven stocks, uncovering a clear divergence between the group’s top and bottom names.

Published

on

Will Tesla Lose Its Spot in the Magnificent Seven?

This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.

In this graphic, we visualize the year-to-date (YTD) performance of the “Magnificent Seven”, a leading group of U.S. tech stocks that gained prominence in 2023 as the replacement of FAANG stocks.

All figures are as of March 12, 2024, and are listed in the table below.

RankCompanyYTD Change (%)
1Nvidia90.8
2Meta44.3
3Amazon16.9
4Microsoft12
5Google0.2
6Apple-6.7
7Tesla-28.5

From these numbers, we can see a clear divergence in performance across the group.

Nvidia and Meta Lead

Nvidia is the main hero of this show, setting new all-time highs seemingly every week. The chipmaker is currently the world’s third most valuable company, with a valuation of around $2.2 trillion. This puts it very close to Apple, which is currently valued at $2.7 trillion.

The second best performer of the Magnificent Seven has been Meta, which recently re-entered the trillion dollar club after falling out of favor in 2022. The company saw a massive one-day gain of $197 billion on Feb 2, 2024.

Apple and Tesla in the Red

Tesla has lost over a quarter of its value YTD as EV hype continues to fizzle out. Other pure play EV stocks like Rivian and Lucid are also down significantly in 2024.

Meanwhile, Apple shares have struggled due to weakening demand for its products in China, as well as the company’s lack of progress in the artificial intelligence (AI) space.

Investors may have also been disappointed to hear that Apple’s electric car project, which started a decade ago, has been scrapped.

Continue Reading

Subscribe

Popular